• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Funding of research center developing nanomaterials for cancer immunotherapy extended

Bioengineer by Bioengineer
June 28, 2017
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The German Research Foundation (DFG) has agreed to fund the Mainz-based Collaborative Research Center (CRC) 1066 "Nanodimensional Polymer Therapeutics for Tumor Therapy" involved in the development of nanomaterials for cancer immunotherapy for another four years to the end of June 2021. This extension confirms Mainz as a major research hub in this field that requires input from both chemistry and biomedicine alike. Contributing to CRC 1066 are the Chemistry, Pharmaceutical Sciences, and Physics institutes at Johannes Gutenberg University Mainz (JGU) together with the Mainz University Medical Center and the Max Planck Institute for Polymer Research (MPI-P) in Mainz. The German Research Foundation will provide nearly EUR 13 million in financing over the next four years.

CRC 1066 is pursuing the development of new, multi-functional nanoparticle drug carriers that can be employed in the immunotherapy of malignant melanomas. "Chemists, biologists, and physicians work together extensively here in three complementary and thus closely integrated areas," explained CRC Coordinator Professor Rudolf Zentel of the Institute of Organic Chemistry at Mainz University. The objective is to use new nano-sized drug carriers to create targeted immune responses that can be used for treatment purposes. This can only be achieved by means of close interdisciplinary collaboration between polymer chemists, physical chemists, and (cancer) immunologists, i.e., three disciplines which traditionally have vastly different methodologies and scientific working methods.

"Over the past three years, we have managed to put in place an excellent foundation for our work on which we now mean to build. The main difficulty at first was learning to understand the various 'languages' used in the other scientific fields," Professor Katharina Landfester, Director of the MPI-P, pointed out. Professor Stephan Grabbe of the Mainz University Medical Center added: "Our findings are being published in internationally eminent journals and we are very proud of the fact that we have recently seen the first fruits of our research being employed for the purpose of clinical trials in patients."

In the second funding period, the CRC will retain its current structure whereby it undertakes primarily polymer-chemical synthesis projects, translational-application oriented projects as well as analytical interdisciplinary projects. At the same time, however, its focus will be more on the actual application of drug carriers created using polymer-chemical processes in biological systems rather than on the polymer synthesis method itself. The fully established collaboration between chemists and immunologists means that most individual projects can be jointly run by polymer chemists and immunologists.

The interdisciplinary nature of the CRC 1066 is reflected by the membership of its board. The board is composed of coordinator Professor Rudolf Zentel of Mainz University and the two vice coordinators Professor Stephan Grabbe of the Department of Dermatology of the Mainz University Medical Center and Professor Katharina Landfester of the Max Planck Institute for Polymer Research. Other members of the board are Professor Detlef Schuppan of the Department of Internal Medicine I of the Mainz University Medical Center and, as the representative for young researchers, Dr. Mathias Barz of the JGU Institute of Organic Chemistry.

###

Further information: http://www.crc1066.uni-mainz.de/

Media Contact

Rudolf Zentel
[email protected]
49-613-139-20361
@uni_mainz_eng

Startseite der JGU

http://www.uni-mainz.de/presse/aktuell/1898_ENG_HTML.php

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Tanshinone I Shields Against Osteonecrosis by Activating Nrf2

September 30, 2025

Exploring Otoliths in Periophthalmodon schlosseri from Vietnam

September 30, 2025

Unstructured Protein Segments: The Key to Regulating Biological Functions

September 30, 2025

Wing Shape Adaptations Enable Small Hoverflies to Maintain Flight

September 30, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    88 shares
    Share 35 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    60 shares
    Share 24 Tweet 15
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cardiovascular Disease Influences Colorectal Cancer Outcomes

NRF2 Enhances Ovarian Cancer Cell Migration via TAGLN

Family, Clinician Views on CHD LIFE Care Pathway

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.